<DOC>
	<DOCNO>NCT01218984</DOCNO>
	<brief_summary>This Phase 2 , multicenter , randomize , double-blind pilot study opioid-using adult assess presence , duration , degree opiate blockade well safety tolerability Medisorb速 naltrexone ( VIVITROL速 ) . Subjects randomized 1:1:1 ratio receive single gluteal intramuscular ( IM ) injection Medisorb naltrexone 75 , 150 , 300 mg .</brief_summary>
	<brief_title>ALK21-004 : Single-dose Opiate Challenge Medisorb速 Naltrexone ( VIVITROL速 ) Adults Who Use Opioids</brief_title>
	<detailed_description>Potential subject screen within 21 day prior dose study drug ( Medisorb naltrexone placebo ) Day 0 . Screening evaluation include baseline hydromorphone challenge session increase dos hydromorphone ( 0 mg [ placebo ] , 3 mg , 4.5 mg , 6 mg ) administer hourly interval produce cumulative dose-response curve . Throughout 4-hour challenge period , subject-rated measure ( Visual Analog Scale [ VAS ] question ) physiological measure ( ie , pupil size ) record . As safety measure , least 7 day baseline hydromorphone challenge , naloxone challenge perform follow 1-day oral naltrexone tolerability assessment . On Day 0 , eligible subject administer single dose study drug . To assess level opiate blockade surmountability attributable Medisorb naltrexone , experimental hydromorphone challenge session conduct postdose Days 7 , 14 , 21 , 28 , 42 , 56 , single placebo hydromorphone challenge administer randomly select visit . Pupil size measure 15 minute prior first hydromorphone dose 15 , 30 , 45 , minute ascend hydromorphone/placebo hydromorphone dose . Blood sample measurement naltrexone 6B-naltrexol obtain screen hydromorphone/placebo administration Days 7 , 14 , 21 , 28 , 42 , 56 . Subjects monitor safety Day 56 .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Primary Adults use opioids : nonmedically least 1 year ; least per week least period use history ; few 3 time per week average 30 day prior screen . Provided write informed consent Demonstrated positive response hydromorphone challenge screen Willing use contraception study duration childbearing potential Primary Any clinically significant medical condition laboratory abnormality screen Participated clinical trial within prior 30 day Dependent opioids Seeking treatment opioid abuse Psychosis major mood anxiety disorder Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Opiate Dependence</keyword>
</DOC>